Robert Honigberg, MD, MBA. Robert is a former surgeon and an experienced clinical leader in a variety of therapeutic areas who taught strategy as a former Adjunct Professor of Health Enterprise Management at Kellogg Business School/ Northwestern University. He is the former Chief Medical Officer of GE Healthcare. He has also held positions of medical leadership in clinical development, business development, and medical affairs at Schering-Plough Oncology, Ortho Biotech, CardioDx, Flexion Therapeutics, Baxalta and Shire. He has designed and executed a myriad of clinical studies and is a current member of the MAPS Evidence Generation Focus Area working group Dr. Honigberg is a graduate from Duke University with a BA in Economics, obtained his medical degree and later MBA from Kellogg School of Management.Mark Devlin
Mark is a CurioTM Director and Executive with more than 30 years of experience in the biopharmaceutical industry. He is a former SVP of Market Access at Allergan, held similar positions at Actavis and Forest Laboratories, and has a deep understanding of the US payer system. He has also consulted for more than a dozen pharma clients, helping with commercial strategy, Hub and patient services, pricing strategy, and business development. Mark has a BS in Biology and Chemistry from Fairleigh Dickinson University and studied at the FW Olin School of Business at Babson College.Haita Makanji
Dr. Haita Makanji joined Magellan Rx Management in 2014. She is currently the vice president of clinical strategy and innovation within specialty in which she assumes several roles and responsibilities, including development and management of specialty clinical programs and interfacing with payers and pharmaceutical companies to bring unique solutions to curb the rising specialty spend. For clinical program development and management, she is responsible for design, implementation, and day-to-day operations of specialty programs that improve the quality of care for patients with high cost disease states including but not limited to rheumatoid arthritis, multiple sclerosis, oncology, and rare diseases such as hemophilia. Furthermore, she oversees the MRx Comprehensive Oncology Management Program which encompasses utilization management with unique strategies to curb the rising spend in oncology and complex case management. A significant portion of her role has also expanded to lead clinical program development efforts for other lines of business including employer groups and Medicaid plans. Additionally, Dr. Makanji leads a team of pharmacists, including board-certified oncology pharmacists who are tasked to support payers and assist with comprehensive medical and pharmacy data analyses, prior authorization and medical policy design, and organizing unique key opinion leader thought leadership panels. Dr. Makanji has been in the healthcare industry for over 10 years. She began her career as a HIV-certified pharmacist at Walgreens and transitioned to managed care in early 2012 with CDMI, LLC (which was later acquired by Magellan Rx Management in 2014). Dr. Makanji earned a Doctor of Pharmacy from Massachusetts College of Pharmacy and Health Sciences in Boston, MA. She is currently a registered pharmacist in both Rhode Island and Connecticut and has additional advanced training in HIV from University of Buffalo, and medication therapy management and immunizations from the American Pharmacists Association (APhA). Dr. Makanji also serves as president of the Northeast affiliate of the Academy of Managed Care Pharmacy (AMCP).